These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30179319)

  • 1. Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption.
    Hübner F; Kasperkiewicz M; Knuth-Rehr D; Shimanovich I; Hübner J; Süfke S; Muck P; Zillikens D; Schmidt E
    J Dtsch Dermatol Ges; 2018 Sep; 16(9):1109-1118. PubMed ID: 30179319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption.
    Müller PA; Bröcker EB; Klinker E; Stoevesandt J; Benoit S
    Dermatology; 2012; 224(3):224-7. PubMed ID: 22678083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption.
    Herrero-González JE; Sitaru C; Klinker E; Bröcker EB; Zillikens D
    Clin Exp Dermatol; 2005 Sep; 30(5):519-22. PubMed ID: 16045683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series.
    Kasperkiewicz M; Schulze F; Meier M; van Beek N; Nitschke M; Zillikens D; Schmidt E
    J Am Acad Dermatol; 2014 Nov; 71(5):1018-20. PubMed ID: 25437968
    [No Abstract]   [Full Text] [Related]  

  • 5. [Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)].
    Raffin D; Delaplace M; Roussel A; Estève E
    Ann Dermatol Venereol; 2013 Dec; 140(12):784-7. PubMed ID: 24315224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-p200 pemphigoid: a spectacular response to dapsone].
    Munsch C; Prey S; Joly P; Meyer N; Lamant L; Livideanu C; Viraben R; Paul C
    Ann Dermatol Venereol; 2011 Nov; 138(11):739-42. PubMed ID: 22078034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases.
    Schmidt E; Kraensel R; Goebeler M; Sinkgraven R; Bröcker EB; Rzany B; Zillikens D
    Cutis; 2005 Sep; 76(3):205-9. PubMed ID: 16268266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.
    Schmidt E; Obe K; Bröcker EB; Zillikens D
    Arch Dermatol; 2000 Feb; 136(2):174-8. PubMed ID: 10677092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunoadsorption in dermatology].
    Hübner F; Kasperkiewicz M; Zillikens D; Schmidt E
    Hautarzt; 2019 Jan; 70(1):51-63. PubMed ID: 30519749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
    van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
    JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.
    Iwata Y; Komura K; Kodera M; Usuda T; Yokoyama Y; Hara T; Muroi E; Ogawa F; Takenaka M; Sato S
    Arch Dermatol; 2008 Jan; 144(1):41-8. PubMed ID: 18209167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linear IgA disease: successful application of immunoadsorption and review of the literature.
    Kasperkiewicz M; Meier M; Zillikens D; Schmidt E
    Dermatology; 2010; 220(3):259-63. PubMed ID: 20130384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole body application of a potent topical corticosteroid for bullous pemphigoid.
    Terra JB; Potze WJ; Jonkman MF
    J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):712-8. PubMed ID: 23551654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid.
    Kasperkiewicz M; Hoppe U; Zillikens D; Schmidt E
    Clin Exp Dermatol; 2010 Aug; 35(6):614-7. PubMed ID: 19874345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid.
    Mersmann M; Dworschak J; Ebermann K; Komorowski L; Schlumberger W; Stöcker W; Zillikens D; Probst C; Schmidt E
    Arch Dermatol Res; 2016 Jan; 308(1):31-8. PubMed ID: 26498290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid.
    Amagai M; Ikeda S; Hashimoto T; Mizuashi M; Fujisawa A; Ihn H; Matsuzaki Y; Ohtsuka M; Fujiwara H; Furuta J; Tago O; Yamagami J; Tanikawa A; Uhara H; Morita A; Nakanishi G; Tani M; Aoyama Y; Makino E; Muto M; Manabe M; Konno T; Murata S; Izaki S; Watanabe H; Yamaguchi Y; Matsukura S; Seishima M; Habe K; Yoshida Y; Kaneko S; Shindo H; Nakajima K; Kanekura T; Takahashi K; Kitajima Y; Hashimoto K;
    J Dermatol Sci; 2017 Feb; 85(2):77-84. PubMed ID: 27876358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
    Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
    Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication.
    Kolesnik M; Becker E; Reinhold D; Ambach A; Heim MU; Gollnick H; Bonnekoh B
    J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):771-80. PubMed ID: 23651052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.
    Fichel F; Barbe C; Joly P; Bedane C; Vabres P; Truchetet F; Aubin F; Michel C; Jegou J; Grange F; Antonicelli F; Bernard P
    JAMA Dermatol; 2014 Jan; 150(1):25-33. PubMed ID: 24226428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.